RUSFERTIDE (PTG-300) ELIMINATES THE NEED FOR THERAPEUTIC PHLEBOTOMY IN BOTH LOW AND HIGH-RISK POLYCYTHEMIA VERA (PV) PATIENTS

EHA Library, Marina Kremyanskaya, 324608

EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY

EHA Library, Andreas Reiter, 324609

TRANSFUSION INDEPENDENCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS RECEIVING MOMELOTINIB

EHA Library, Ruben Mesa, 324610

OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH FEDRATINIB AS FIRST-LINE MYELOFIBROSIS (MF) THERAPY AND AFTER PRIOR RUXOLITINIB (RUX): RESULTS FROM THE JAKARTA AND JAKARTA2 TRIALS

EHA Library, Claire Harrison, 324611

JAKTINIB, A NOVAL JAK INHIBITOR IN TREATMENT OF PATIENTS WITH ADVANCED MYELOFIBROSIS: PRELIMINARY RESULTS FROM A PHASE 2 STUDY

EHA Library, Yi Zhang, 324612

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: A 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)

EHA Library, Martin Hutchings, 324613

CAMRELIZUMAB FOR RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: THREE-YEAR OUTCOME OF A MULTICENTER, PHASE 2 STUDY

EHA Library, Jianqiu Wu, 324614

TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY

EHA Library, Yuqin Song, 324615

PREDICTIVE VALUE OF QUANTITATIVE 18F-FDG-PET RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA

EHA Library, Julia Driessen, 324616

BRENTUXIMAB VEDOTIN-CONTAINING ESCALATED BEACOPP VARIANTS FOR NEWLY DIAGNOSED ADVANCED CLASSICAL HODGKIN LYMPHOMA: FOLLOW-UP ANALYSIS OF A RANDOMIZED PHASE II STUDY FROM THE GERMAN HODGKIN STUDY GROUP

EHA Library, Carla Damaschin, 324617

EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL

EHA Library, Martin Dreyling, 324618

CHRONOS-3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON-HODGKIN LYMPHOMA

EHA Library, Pier Luigi Zinzani, 324619

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (R/R INHL): PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.

EHA Library, Charles Herbaux, 324620

OUTCOMES IN ZUMA-5 WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WHO HAD THE HIGH-RISK FEATURE OF EARLY PROGRESSION AFTER FIRST CHEMOIMMUNOTHERAPY

EHA Library, Caron Jacobson, 324621

TOLERABILITY AND EFFICACY OF THE COMBINATION OF PI3KΔ INHIBITOR ZANDELISIB (ME-401) AND BTK INHIBITOR ZANUBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) B-CELL MALIGNANCIES: INITIAL RESULTS

EHA Library, Jacob D. Soumerai, 324622

HIGH INCIDENCE OF PROLONGED COVID-19 AMONG PATIENTS WITH LYMPHOMA TREATED WITH B-CELL DEPLETING IMMUNOTHERAPY

EHA Library, Caroline Besson, 324623

FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR-T CELLS AND ENROLLED IN DESCAR-T REGISTRY, A FRENCH REAL-LIFE DATABASE FOR CAR-T CELLS IN HEMATOLOGIC MALIGNANCIES.

EHA Library, Steven Le, 324624

GENETIC LANDSCAPES AND CURATIVE EFFECT OF CAR T CELLS IMMUNOTHERAPY IN RELAPSE AND REFRACTORY DLBCLS

EHA Library, Hui Shi, 324625

FIRST-IN-HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS-3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS

EHA Library, Shigeru Kusumoto, 324626

MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PRIMARY CNS LYMPHOMA: RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS

EHA Library, Gerald Illerhaus, 324627

IMPACT OF ETOPOSIDE AND AUTOLOGOUS STEM-CELL TRANSPLANTATION ON SURVIVAL AMONG YOUNG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN THE NETHERLANDS; A NATIONWIDE, POPULATION-BASED COHORT STUDY

EHA Library, Mirian Brink, 324628

INTER-B NHL RITUX 2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN’S LYMPHOMA/ACUTE LEUKAEMIA: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY.

EHA Library, Veronique Minard-Colin, 324629

PROMISING TOLERABILITY AND EFFICACY RESULTS FROM DOSE-ESCALATION IN AN ONGOING PHASE IB/II STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

EHA Library, Nilanjan Ghosh, 324630

PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH-DOSE METHOREXATE (R2-MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTAINANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 324631

NO DIFFERENCE IN OVERALL SURVIVAL BETWEEN R-CHOP AND R-EPOCH AMONG PATIENTS WITH ADVANCED STAGE MYC-REARRANGED, DOUBLE HIT, OR TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Tylan Magnusson, 324632

CIRCULATING TUMOR DNA SEQUENCING REVEALS THE GENOMIC LANDSCAPE OF HODGKIN LYMPHOMA AND FACILITATES HIGHLY SENSITIVE DETECTION OF MINIMAL RESIDUAL DISEASE

EHA Library, Sven Borchmann, 324633

A COMPREHENSIVE SINGLE-CELL ATLAS OF NONHEMATOPOIETIC CELLS IN HUMAN LYMPH NODE AND LYMPHOMA REVEALS LANDSCAPE OF STROMAL REMODELING

EHA Library, Yoshiaki Abe, 324634

TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA

EHA Library, Alessandra Venanzi °, 324635

BLOCKADE OF NCAPD3 AS A NOVEL THERAPEUTIC APPROACH IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Juan Yang, 324636

A SYSTEMS BIOLOGY APPROACH TO DLBCL PREDICTS EMERGENT PHENOTYPES FROM MOLECULAR DYSREGULATION AND IDENTIFIES DISTINCT ROLES FOR NF-KB SUBUNITS CREL AND RELA.

EHA Library, Simon Mitchell, 324637

RESTORING M1/M2 MACROPHAGE POLARIZATION VIA UP-REGULATING PI3K-AKT PATHWAY ALLEVIATES PROLONGED ISOLATED THROMBOCYTOPENIA POST-ALLOTRANSPLANT

EHA Library, HongYan Zhao, 324638

DISULFIRAM ALLEVIATES ACUTE GRAFT-VERSUS-HOST DISEASE BY INHIBITING MACROPHAGE PYROPTOSIS

EHA Library, Xue-Yan Sun, 324639

DISEASE RISK IN TP53 MUTANT ACUTE MYELOID LEUKAEMIA FOLLOWING AN ALLOGENEIC STEM CELL TRANSPLANT IS DEPENDENT ON THE PRESENCE OF CO-EXISTING CYTOGENETIC FEATURES: A REPORT FROM THE ALWP OF THE EBMT

EHA Library, Justin Loke, 324640

THE ROLE OF PRE -TRANSPLANTATION MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS WITH AML IN REMISSION TRANSPLANTED FROM UNRELATED DONORS WITH POST TRANSPLANT CYCLOPHOSPHAMIDE: FROM THE ALWP OF THE EBMT

EHA Library, Arnon Nagler, 324641

AN INTEGRATIVE SCORING SYSTEM MAINLY BASED ON QUANTITATIVE DYNAMICS OF MINIMAL/MEASURABLE RESIDUAL DISEASE FOR RELAPSE PREDICTION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Rui Ma, 324642

IBRUTINIB VS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PATIENTS WITH NEW-ONSET CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND PHASE 3 INTEGRATE STUDY

EHA Library, David Miklos, 324643

EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH2 STUDY

EHA Library, Jeffrey Szer, 324644

A PHASE 1 TRIAL OF THE HEDGEHOG SIGNALLING INHIBITOR GLASDEGIB IN PATIENTS WITH REFRACTORY SCLEROTIC CHRONIC GRAFT-VERSUS-HOST DISEASE

EHA Library, Eduardo Rodríguez-Arbolí, 324645

INTERIM RESULTS FROM THE EQUATE STUDY: PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, John Koreth, 324646

BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213)

EHA Library, Corey Cutler, 324647

PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASE INHIBITORS POST-ALLOGENEIC STEM CELL TRANSPLANTATION IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SUBANALYSIS OF GITMO PH-POSITIVE ALL STUDY.

EHA Library, Anna Candoni, 324648

NARSOPLIMAB (OMS721) TREATMENT CONTRIBUTES TO IMPROVEMENTS IN ORGAN FUNCTION IN ADULT PATIENTS WITH HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

EHA Library, Miguel-Angel Perales, 324649

FLUDARABINE AND TBI 8 GY VERSUS FLUDARABINE AND TREOSULFAN CONDITIONING IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

EHA Library, Gesine Bug, 324650

CMML PATIENTS UNDERGOING ALLOGENEIC HCT HAVE INFERIOR SURVIVAL OUTCOMES IN COMPARISON WITH MDS PATIENTS DUE TO A SIGNIFICANTLY HIGHER RELAPSE RATE. A REGISTRY STUDY OF THE EBMT-CMWP

EHA Library, Alicia Rovó, 324651

AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMA-NOT OTHERWISE SPECIFIED AND ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA FAILING FIRST-LINE THERAPY

EHA Library, Kazuaki Kameda, 324652

INFLAMMATORY-RESPONDING MESENCHYMAL STROMAL CELLS MODULATE THE DYNAMIC BONE MARROW MICROENVIRONMENT RESPONSE TO STRESS

EHA Library, Shubhankar Sood, 324653

DORMANCY PROTECTS FUNCTIONAL POTENTIAL OF HEMATOPOIETIC STEM CELLS UNDER HOMEOSTATIC AND STRESS CONDITIONS

EHA Library, Ana-Matea Mikecin Drazic, 324654

MICROENVIRONMENTAL SFRP1 REGULATES REPOPULATING ACTIVITY OF HEMATOPOIETIC STEM CELLS VIA PP2A-MEDIATED REGULATION OF CTNNB1/EP300

EHA Library, Robert A.J. Oostendorp, 324655

LOW-CYTOKINE ENVIRONMENT DETERMINES THE OUTCOME OF EMBRYONIC HEMATOPOIESIS IN MOUSE FETAL LIVER

EHA Library, Francisca Soares-Da-Silva, 324656

REDUCED LEVELS OF THROMBOPOIETIN CONTRIBUTE TO IMPAIRED HEMATOPOIETIC STEM CELL FUNCTION AND DEFECTIVE MEGAKARYOPOIESIS IN ΒETA-THALASSEMIA

EHA Library, Annamaria Aprile, 324657

ADCLEC.SYN1, A COMBINATORIAL CAR PLATFORM FOR AML

EHA Library, Sascha Haubner, 324658

PRECLINICAL DATA SUPPORTING THE INITIATION OF THE EDIT-301 PHASE I RUBY CLINICAL TRIAL FOR THE POTENTIAL TREATMENT OF SICKLE CELL DISEASE

EHA Library, Edouard De Dreuzy, 324659

LAG-3, TIM-3 OR 2B4 DISRUPTION DIFFERENTIALLY REGULATE THE ANTI-TUMOR RESPONSE OF TCR GENE EDITED HUMAN MEMORY STEM T CELLS

EHA Library, Beatrice Claudia Cianciotti, 324660

ENGINEERED REGULATORY T CELLS USING ORTHOGONAL IL-2 CYTOKINE-RECEPTOR COMPLEXES PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE.

EHA Library, Teresa Ramos, 324661

CORD-BLOOD-DERIVED T AND NATURAL KILLER CELLS ENGINEERED VIA THE PIGGYBAC TRANSPOSON SYSTEM TO EXPRESS A LIGAND-BASED CAR TARGETING THE CD116/CD131 COMPLEX

EHA Library, Hirokazu Morokawa, 324662

POLATUZUMAB VEDODTIN VS. CAR-T CELL FOR PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA - A PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Irit Avivi Mazza, 324663

26 WEEK EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT; AMT-061) IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B TREATED IN THE PHASE 3 HOPE-B CLINICAL TRIAL

EHA Library, Wolfgang Miesbach, 324664

BETIBEGLOGENE AUTOTEMCEL GENE THERAPY FOR THE TREATMENT OF TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED LONG-TERM EFFICACY AND SAFETY RESULTS

EHA Library, Evangelia Yannaki, 324665

RETROVIRAL GENE THERAPY FOR THE TREATMENT OF ADA-SCID: LONG-TERM FOLLOW UP AND FIRST CASE OF T-CELL ACUTE LEUKAEMIA DUE TO INSERTIONAL MUTAGENESIS

EHA Library, Maria Pia Cicalese, 324666

A PHASE I-IIA STUDY OF GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM STUDY)

EHA Library, Fabio Ciceri, 324667

SAFETY AND EFFICACY OF VOXELOTOR IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE AGED 4-11 YEARS

EHA Library, Clark Brown, 324668

COMPLETE RESOLUTION OF SEVERE VASO-OCCLUSIVE EVENTS AND IMPROVED PATHOPHYSIOLOGY WITH LENTIGLOBIN GENE THERAPY IN SICKLE CELL DISEASE (SCD): ONGOING PHASE 1/2 HGB-206 GROUP C STUDY

EHA Library, Janet L. Kwiatkowski, 324669

ISCHEMIC WHITE MATTER LESIONS ARE ASSOCIATED WITH COGNITIVE DYSFUNCTION IN ADULTS WITH SICKLE CELL DISEASE

EHA Library, Florence Blais, 324670

THE SAFETY, PHARMACOKINETICS & PHARMACODYNAMIC EFFECTS OF IMR-687, A HIGHLY-SELECTIVE PDE9 INHIBITOR, IN ADULTS WITH SICKLE CELL DISEASE: PHASE-2A PLACEBO-CONTROLLED & OPEN-LABEL EXTENSION STUDIES

EHA Library, Biree Andemariam, 324671

DIFFERENTIAL ENDOTHELIAL VCAM1 EXPRESSION AND IMPLICATIONS FOR SICKLE CELL ANEMIA VASCULOPATHY

EHA Library, Marisa Silva, 324672

MIR-451 FUNCTION ON ULK1-MEDIATED AUTOPHAGY OF FREE ΑLPHA-GLOBIN IN ΒETA-THALASSEMIA

EHA Library, Christophe Lechauve, 324673

BETIBEGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED RESULTS FROM HGB-207 (NORTHSTAR-2) AND HGB-212 (NORTHSTAR-3)

EHA Library, Franco Locatelli, 324674

RESULTS FROM A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

EHA Library, Kevin Kuo, 324675

INHIBITION OF FIBROBLAST GROWTH FACTOR-23 (FGF-23) AS A NOVEL STRATEGY TO TARGET BONE AND HEMATOPOIETIC STEM CELL NICHE DEFECTS IN ΒETA-THALASSEMIA

EHA Library, Annamaria Aprile, 324676

TGF-BETA SIGNALING CONTROLS THE LINEAGE CELL FATE OF HEMATOPOIETIC STEM CELLS TOWARDS ERYTHROID BRANCHING IN BETA-THALASSEMIA

EHA Library, Maria Rosa Lidonnici, 324677

ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED

EHA Library, Hanny Al-Samkari, 324678

ACTIVATE-T: A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED

EHA Library, Andreas Glenthøj, 324679

IDENTIFICATION OF A NOVEL GENE CAUSING AN AUTOSOMAL RECESSIVE FORM OF CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE III

EHA Library, Gonzalo Hernández, 324680

ESTABLISHMENT AND PHENOTYPING OF VIABLE MOUSE MODELS OF X-LINKED SIDEROBLASTIC ANEMIA AND PROTOPORPHYRIA USING CRISPR-CAS9 EDITING

EHA Library, Sarah Ducamp, 324681

METABOLIC FINGERPRINT IN HEREDITARY SPHEROCYTOSIS CORRELATES WITH RED BLOOD CELL CHARACTERISTICS AND CLINICAL SEVERITY

EHA Library, Birgit Van Dooijeweert, 324682

HEPATOCYTES INSTRUCT LIVER SINUSOIDAL ENDOTHELIAL CELLS TO INDUCE BMP6 IN RESPONSE TO IRON

EHA Library, Silvia Colucci, 324683

NEW INSIGHTS INTO PATHOGENIC MECHANISMS OF HEPATIC IRON METABOLISM DUE TO PIEZO1 GAIN OF FUNCTION VARIANTS.

EHA Library, Immacolata Andolfo, 324684

ANEMIA OF CHRONIC KIDNEY DISEASE IS PREVENTED THROUGH TRANSFERRIN RECEPTOR 2 INHIBITION

EHA Library, Violante Olivari, 324685

LOSS OF ERYTHROBLASTS IN ACUTE MYELOID LEUKEMIA CAUSES IRON REDISTRIBUTION WITH CLINICAL IMPLICATIONS

EHA Library, Delfim Duarte, 324686

HEPCIDIN IS A MARKER OF COVID-19 SEVERITY AND MORTALITY IN A COHORT OF HOSPITALIZED ITALIAN PATIENTS

EHA Library, Laura SILVESTRI, 324687

DEVELOPMENT OF NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 IN HEALTHY SANITARY WORKERS AND OCTOGENARIANS POST-BNT162B2 MRNA COVID-19 VACCINE: FIRST RESULTS OF A PROSPECTIVE TRIAL IN 366 INDIVIDUALS

EHA Library, evangelos Terpos, 324688

EHA GUIDELINE: ANTIFUNGAL PROPHYLAXIS IN ACUTE MYELOID LEUKEMIA TREATED WITH NOVEL AGENTS

EHA Library, Jannik Stemler, 324689

RATIONAL: A RANDOMISED CONTROLLED FEASIBILITY TRIAL COMPARING PROPHYLACTIC IMMUNOGLOBULIN WITH ANTIBIOTICS IN PATIENTS WITH ACQUIRED HYPOGAMMAGLOBULINEMIA SECONDARY TO HAEMATOLOGICAL MALIGNANCIES

EHA Library, Zoe McQuilten, 324690

BASELINE CT THORAX AND RISK OF INVASIVE FUNGAL DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Varun Mehra, 324691

EARLY INFECTIONS FOLLOWING COMMERCIAL ANTI-CD19 CAR-T CELLS INFIRM POPULATION – A SINGLE CENTER RETROSPECTIVE STUDY

EHA Library, Ofrat Beyar-Katz, 324692

SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE IN PATIENTS AFTER ALLOGENEIC HCT AND CD19-BASED CAR-T THERAPY – A SINGLE CENTER PROSPECTIVE COHORT STUDY

EHA Library, Ron Ram, 324693

OUTCOMES IN PATIENTS WITH ACUTE LEUKAEMIA AND COVID-19: RESULTS OF SUBGROUP ANALYSIS OF CHRONOS19 REGISTRY

EHA Library, Olga Aleshina Gavrilina, 324694

KINETICS OF ANTIBODIES AGAINST SARS-COV-2 IN CONVALESCENT PLASMA DONORS AFTER EIGHT MONTHS FROM COVID-19: PERSISTENCE OF SPIKE ANTIBODIES BUT LOSS OF NEUTRALIZING ANTIBODIES IN 24% OF DONORS

EHA Library, evangelos Terpos, 324695

COVID-19 AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A NATIONAL ISRAELI RETROSPECTIVE ANALYSIS

EHA Library, Ilana Levy Yurkovski, 324696

SEROCONVERSION AND LONGEVITY OF ANTI SARS-COV-2 ANTIBODIES IN ONCO-HEMATOLOGIC PATIENTS WHO EXPERIENCED SARS-COV-2 INFECTION.

EHA Library, Anna Candoni, 324697

SUTIMLIMAB, A TARGETED COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE (QOL) IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CADENZA STUDY

EHA Library, Alexander Röth, 324698

C1S-TARGETED INHIBITION OF CLASSICAL COMPLEMENT PATHWAY BY SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): EFFICACY AND SAFETY RESULTS FROM THE RANDOMIZED, PLACEBO (PBO)-CONTROLLED PHASE 3 CADENZA STUDY

EHA Library, Alexander Röth, 324699

HEMOSTATIC CHARACTERIZATION OF POST-COVID-19 CONVALESCENT PLASMA DONORS: THE BERGAMO EXPERIENCE

EHA Library, Carmen Tartari, 324700

DESCRIPTION OF THE INFLAMMATORY PROFILE WITH 45 CYTOKINES ACCORDING TO ABO BLOOD GROUP IN COVID-19 AND ITS IMPLICATIONS ON SEVERITY AND MORTALITY.

EHA Library, Alvaro Tamayo-Velasco, 324701

LARGE-SCALE PRODUCTION OF CULTURED ERYTHROCYTES USING BIOREACTORS

EHA Library, Marie-José Claessen, 324702

A RESERVOIR OF RITUXIMAB-RESISTANT SPLENIC MEMORY B CELLS CONTRIBUTES TO RELAPSES AFTER B-CELL DEPLETION THERAPY

EHA Library, Etienne Crickx, 324703

LONG-TERM SURVIVAL IN PATIENTS WITH PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA - A NATIONWIDE POPULATION-BASED COHORT STUDY

EHA Library, Nikolaj Mannering, 324704

FEATURES OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IDENTIFIED THROUGH SINGLE-CELL RNA SEQUENCING IN IMMUNE THROMBOCYTOPENIA

EHA Library, Yan Liu, 324705

HIGH LEVEL OF ESTRADIOL INDUCES MEGAKARYOCYTE APOPTOSIS AND IMPAIRS PROPLATELET FORMATION VIA MST1-FOXO1 AXIS DURING PREGNANCY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA

EHA Library, Qi Chen, 324706

PHASE I/II UPDATED SAFETY AND EFFICACY RESULTS OF ORAL BRUTON TYROSINE KINASE (BTK) INHIBITOR RILZABRUTINIB IN RELAPSED/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, David Kuter, 324707